MedTrace Logo

A 4 Week Study to Investigate the Safety and Tolerability of AZD5069 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT01233232 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 109

Last updated 2015-09-17

Study results available
· View outcomes & findings →

Summary

The purpose of this study is the evaluate the safety and tolerability of AZD5069 in patients with Chronic Obstructive Pulmonary Disease

Conditions

  • Scientific Terminology Chronic Obstructive Pulmonary Disease (COPD)
  • Laymen Terminology Chronic Bronchitis and Emphysema

Interventions

DRUG

Placebo

Oral dose bid

DRUG

AZD5069 50mg

Oral dose bid

DRUG

AZD5069 80mg

Oral dose bid

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2011-03-31
Completion
2011-03-31

Countries

  • Bulgaria
  • Germany
  • Hungary
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01233232 on ClinicalTrials.gov